gingerol and Diabetic-Cardiomyopathies

Diabetes mellitus (DM) can induce cardiomyocyte injury and lead to diabetic cardiomyopathy (DCM) which presently has no specific treatments and consequently increase risk of mortality.. To characterize the therapeutic effect of 6-gingerol (6-G) on DCM and identify its potential mechanism.. These findings suggest that 6-G could protect against DCM by the mechanism of ferroptosis inhibition and inflammation reduction via enhancing the Nrf2/HO-1 pathway.

Topics: Animals; Diabetes Mellitus; Diabetic Cardiomyopathies; Glucose; Inflammation; Mice; NF-E2-Related Factor 2; Oxidative Stress; Palmitic Acid; Rats; Superoxide Dismutase

The current study was conducted to evaluate the effect of 6-gingerol (6G) on cardiac complications in streptozotocin (STZ)-induced diabetic (DM) rats. STZ-induced DM rats (single 50 mg/kg i.p. injection, 15 days prior to drug treatment) or time-matched controls were treated with 6G (75 mg/day route orally). After a further 8 weeks, blood was collected for biochemical analysis and 8-isoprostenol was measured in urine. Cardiac hemodynamics and ECG was assessed. 6G significantly attenuated the increased level of blood glucose in diabetic rats and improved cardiac hemodynamics in including RR interval, max dP/dt, min dP/dt and Tau. In addition, 6G alleviated the elevated ST segment, T amplitude and R amplitude with no significant effect on disturbed levels of adiponectin, TGF-β or 8-isoprostenol induced by diabetes. The results showed that treatment with 6G has an ameliorative effect on cardiac dysfunction induced by diabetes. Which may be not related to its potential antioxidant effect.

Topics: Animals; Cardiotonic Agents; Catechols; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Dose-Response Relationship, Drug; Fatty Alcohols; Hypoglycemic Agents; Male; Rats; Rats, Wistar; Treatment Outcome